Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Diwakar Davar"'
Autor:
Jennifer Bordeaux, Dustin McCurry, Arivarasan Karunamurthy, Lisa H. Butterfield, Rogerio I. Neves, Anil Pahuja, Matthew P. Holtzman, Beiru Chen, Jehovana Orozco Bender, Ahmad A. Tarhini, Yan Zang, Ju Young Kim, John M. Kirkwood, Yan Lin, Cindy Sander, Joseph J. Skitzki, IlaSri B. Summit, Marc S. Ernstoff, Christian Laing, Joseph J. Drabick, Yana G. Najjar, Huang Lin, Jennifer Tsau, Ghanashyam Sarikonda, Igor Puzanov, Hassane M. Zarour, Zeni Alfonso, Amy Rose, James F. Pingpank, Diwakar Davar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 15
Purpose:Neoadjuvant immunotherapy may improve the clinical outcome of regionally advanced operable melanoma and allows for rapid clinical and pathologic assessment of response. We examined neoadjuvant pembrolizumab and high-dose IFNα-2b (HDI) therap
Publikováno v:
OncoTargets and Therapy. 13:10039-10061
Toll-like receptor 9 (TLR9) is a pattern recognition receptor that is predominantly located intracellularly in immune cells, including dendritic cells, macrophages, natural killer cells, and other antigen-presenting cells (APC). The primary ligands f
Autor:
Jeffrey E. Gershenwald, Michael T. Tetzlaff, Peter A. Prieto, Jennifer L. McQuade, Charlotte E. Ariyan, Jonathan S. Zager, David F. McDermott, Adil Daud, Christian U. Blank, Kim Margolin, Richard A. Scolyer, Brett W. Carter, Elizabeth M. Burton, Richard D. Carvajal, Jeffrey A. Sosman, Alexander N. Shoushtari, April K.S. Salama, Scott E. Woodman, Tina J. Hieken, Vernon K. Sondak, Douglas S. Tyler, Jeffrey E. Lee, Frances C. Wright, Omid Hamid, David E. Fisher, Tanja D. de Gruijl, Miles C. Andrews, Michael C. Lowe, John M. Kirkwood, Keith T. Flaherty, Mark B. Faries, Grant A. McArthur, Dirk Schadendorf, Alexander C.J. van Akkooi, Alberto Fusi, Bart A. van de Wiel, James Larkin, Ken K. Tanabe, Jane L. Messina, Jennifer A. Wargo, Rodabe N. Amaria, Jonathan Cohen, Shaneen Sandhu, Andrew J. Spillane, Reinhard Dummer, Robert Antdbacka, Michael A. Postow, Michael D. Farwell, Céleste Lebbé, Jason J. Luke, Genevieve M. Boland, Tara C. Mitchell, David H. Lawson, Elisa A. Rozeman, Diwakar Davar, Caroline Robert, Kathryn Bollin, Ryan J. Sullivan, Michael A. Davies, Matteo S. Carlino, Isabella C. Glitza, Robyn P. M. Saw, Merrick I. Ross, Axel Hauschild, Teresa M. Petrella, Paolo A. Ascierto, Serigne Lo, Igor Puzanov, Samra Turajlic, Angela Hong, Roland L. Bassett, Keith A. Delman, Georgina V. Long, Hussein Abdul-Hassan Tawbi, Susan M. Swetter, Janis M. Taube, Alexander M.M. Eggermont, John F. Thompson, Donald A. Berry, Leslie A. Fecher, Matthew S. Block, Alexander M. Menzies, David E. Gyorki, Helen Rizos
Publikováno v:
The Lancet Oncology. 20:e378-e389
Advances in the treatment of metastatic melanoma have improved responses and survival. However, many patients continue to experience resistance or toxicity to treatment, highlighting a crucial need to identify biomarkers and understand mechanisms of
Autor:
Diwakar Davar, Saro Sarkisian
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 12, Pp 2553-2565 (2018)
Drug Design, Development and Therapy
Drug Design, Development and Therapy
Saro Sarkisian,1 Diwakar Davar2 1Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, PA, USA; 2Division of Hematology-Oncology, Hillman Cancer Center and University of Pittsburgh, Pittsburgh, PA, USA Abstract: Melanoma is inc
Autor:
Yana G. Najjar, Diwakar Davar, Xi Yang, Saba Shaikh, Greg M. Delgoffe, Yan Zang, Amy Rose, John M. Kirkwood, Hassane M. Zarour, Hong Wang, Jason J. Luke, Cindy Sander
Publikováno v:
Regular and young investigator award abstracts.
Background Immunotherapy has changed the treatment landscape for melanoma, although many patients (pts) do not respond to treatment. While there are likely multiple mechanisms of resistance at play, one key mechanism is the generation of an immunosup
Autor:
Hassane M. Zarour, Joe-Marc Chauvin, Richelle DeBlasio, Diwakar Davar, Ornella Pagliano, Douglas J. Hartman, Arivarasan Karunamurthy, Amy Rose, John M. Kirkwood, Quanquan Ding
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Neoadjuvant PD-1 blockade produces major pathological responses (MPR) in ~30% of patients (pts) with high-risk resectable melanoma (MEL) with durable relapse-free benefit, and increased circulating activated CD8+ T cells.1 2 CMP-001 is a t
Autor:
Andres Forero-Torres, Ecaterina Ileana Dumbrava, Rachel E. Sanborn, Elena Garralda, Alex F. Herrera, Giuseppe Curigliano, Vincent Ribrag, Diwakar Davar, Amitkumar Mehta, Carmen Belli, Stephen M. Ansell, Honey Kumar Oberoi, Clémentine Sarkozy, Jasmine Zain
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundT-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory domains (TIGIT), and costimulatory receptor CD226 competitively bind 2 ligands, CD155 and CD112, which are expressed by tumor cells and antigen-presentin
Publikováno v:
Current oncology reports. 22(8)
Neoadjuvant therapy in melanoma is an area of active investigation with numerous completed and ongoing trials studying a variety of therapeutic interventions utilizing diverse designs. Here, we review completed and ongoing neoadjuvant trials in melan
Autor:
Hassane M. Zarour, Diwakar Davar
Publikováno v:
Biomarkers for Immunotherapy of Cancer ISBN: 9781493997725
Methods Mol Biol
Methods Mol Biol
Tumor development is characterized by the accumulation of mutational and epigenetic changes that transform normal cells and survival pathways into self-sustaining cells capable of untrammeled growth. Although multiple modalities including surgery, ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c96bab0394177e85f73e465a3037e92e
https://doi.org/10.1007/978-1-4939-9773-2_2
https://doi.org/10.1007/978-1-4939-9773-2_2
Autor:
Hassane M. Zarour, Richelle DeBlasio, Marc Schwartz, Stephanie Prescott, Ivan Vujkovic-Cvijin, Amy Rose, Marie Vétizou, Scarlett J. Ernst, Jonathan H. Badger, Howard M. Dubner, Hong Wang, Yasmine Belkaid, John M. Kirkwood, Ascharya K. Balaji, Amiran Dzutsev, Diwakar Davar, Yana G. Najjar, Quanquan Ding, Raquel Galvão Figueredo Costa, Joe-Marc Chauvin, Shuowen Zhang, Carmine Menna, Amir A. Borhani, Giorgio Trinchieri, John A. McCulloch, Bochra Zidi, Richard R. Rodrigues, Ornella Pagliano, Miriam R. Fernandes, Andrey Morgun, Robert M. Morrison, Alicia M. Cole
Publikováno v:
Cancer Research. 81:LB062-LB062
Background: Monoclonal antibodies (mAb) targeting the programmed cell death protein 1 (PD-1) receptor provide durable long-term benefit in a subset of patients (pts) with advanced melanoma with response rates of 35-42% and 4-year progression-free sur